Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Ledermann

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
British Journal of Cancer|March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Journal of the National Cancer Institute|July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard, Michael Lind, Christopher Twelves, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The Lancet. Oncology|April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.
Gynecologic Oncology|April 29, 2025
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trialAndrés Poveda, Stéphanie Lheureux, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2021
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemicAlexandra Taylor, Sudha S Sundar, Rebecca Bowen, et al.
Journal of Gynecologic Oncology|May 26, 2017
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator ConferenceJi Yon Agnes Jang, Nozomu Yanaihara, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 22, 2020
British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)Claire Newton, Andy Nordin, Philip Rolland, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
British Journal of Cancer|March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Journal of the National Cancer Institute|July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard, Michael Lind, Christopher Twelves, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The Lancet. Oncology|April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.
Gynecologic Oncology|April 29, 2025
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trialAndrés Poveda, Stéphanie Lheureux, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2021
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemicAlexandra Taylor, Sudha S Sundar, Rebecca Bowen, et al.
Journal of Gynecologic Oncology|May 26, 2017
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator ConferenceJi Yon Agnes Jang, Nozomu Yanaihara, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 22, 2020
British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)Claire Newton, Andy Nordin, Philip Rolland, et al.
Pageof 5